Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Months Report from the Phase 3 Study of Plerixafor+G-CSF VS. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with NHL.

John F. DiPersio, MD, PhD, Ivana NM Micallef, Patrick J. Stiff, MD, Brian J. Bolwell, MD, Richard Thomas Maziarz, MD, Gary Bridger, PhD, Gary Calandra, MD, PhD

Blood (2008) 112 (11): 1136.

https://doi.org/10.1182/blood.V112.11.1136.1136

Published: 2008

Journal Articles

12 Months Report from a Phase 3 Study of Plerixafor+G-CSF Vs. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with Multiple Myeloma

John F. DiPersio, MD, PhD, Edward A. Stadtmauer, MD, Auayporn P. Nademanee, Ivana NM Micallef, MD, Patrick J. Stiff, MD, Gary Bridger, PhD, Gary Calandra, MD, PhD

Blood (2008) 112 (11): 3312.

https://doi.org/10.1182/blood.V112.11.3312.3312

Published: 2008

Journal Articles

Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Following Autologous Hematopoietic Stem Cell Transplant in Patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma.

Patrick J. Stiff, MD, Ivana NM Micallef, Auayporn P. Nademanee, Edward A. Stadtmauer, MD, Richard Thomas Maziarz, MD, Brian J. Bolwell, MD, Gary Bridger, PhD, Gary Calandra, MD, PhD, Jennifer Angell, MS, John F. DiPersio, MD, PhD

Blood (2008) 112 (11): 2175.

https://doi.org/10.1182/blood.V112.11.2175.2175

Published: 2008

Journal Articles

The CXCR4-Antagonist AMD3100 Augments the Number of Mobilized Peripheral Blood Progenitor Cells (PBPC) When Added to a G-CSF Standard Mobilization Regime and AMD3100-Mobilized PBPC Result in Rapid Hematopoietic Reconstitution after Autologous Transplantation.

Stefan Fruehauf, MD, Timon Seeger, Julian Topaly, MD, Doris Herrmann, PhD, Falk Dillmann, Per Humpert, MD, Gary Calandra, MD, PhD, Stephanie Laufs, PhD, Hartmut Goldschmidt, MD, Anthony D. Ho, MD

Blood (2005) 106 (11): 1961.

https://doi.org/10.1182/blood.V106.11.1961.1961

Published: 2005

Journal Articles

The CXCR4 Antagonist AMD3100 Mobilizes a More Primitive Subset of CD34+ Cells Than G-CSF.

Timon Seeger, Marlon Veldwijk, PhD, Gary Bridger, PhD, Gary Calandra, MD, PhD, Hartmut Goldschmidt, MD, Anthony Ho, MD, Stefan Fruehauf, MD

Blood (2005) 106 (11): 1969.

https://doi.org/10.1182/blood.V106.11.1969.1969

Published: 2005

Journal Articles

CD34+ Cells Mobilized with the New CXCR4 Antagonist AMD3100 + G-CSF Show Increased Anti-Apoptotic, Cell Cycle, DNA Repair and Cell Motility-Associated Gene Expression When Compared to G-CSF Mobilization Alone.

Timon Seeger, Patrick Maier, PhD, Li Li, PhD, Stephanie Laufs, PhD, Volker Eckstein, PhD, Gary Bridger, PhD, Gary Calandra, MD, PhD, Frederik Wenz, MD, Hartmut Goldschmidt, MD, Anthony D. Ho, MD, Stefan Fruehauf, MD

Blood (2005) 106 (11): 4264.

https://doi.org/10.1182/blood.V106.11.4264.4264

Published: 2005

Journal Articles

AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.

Patrick Stiff, MD, Ivana Micallef, MD, Philip McCarthy, MD, Margarida Magalhaes-Silverman, MD, Neal Flomenberg, MD, Daniel Weisdorf, MD, Guido Tricot, MD, Mary Territo, MD, Rafat Abonour, MD, Karin Badel, Gary Calandra, MD/PhD

Blood (2004) 104 (11): 2847.

https://doi.org/10.1182/blood.V104.11.2847.2847

Published: 2004

NARROW

Months Report from the Phase 3 Study of Plerixafor+G-CSF VS. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with NHL.

12 Months Report from a Phase 3 Study of Plerixafor+G-CSF Vs. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with Multiple Myeloma

Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Following Autologous Hematopoietic Stem Cell Transplant in Patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma.

The CXCR4-Antagonist AMD3100 Augments the Number of Mobilized Peripheral Blood Progenitor Cells (PBPC) When Added to a G-CSF Standard Mobilization Regime and AMD3100-Mobilized PBPC Result in Rapid Hematopoietic Reconstitution after Autologous Transplantation.

The CXCR4 Antagonist AMD3100 Mobilizes a More Primitive Subset of CD34+ Cells Than G-CSF.

CD34+ Cells Mobilized with the New CXCR4 Antagonist AMD3100 + G-CSF Show Increased Anti-Apoptotic, Cell Cycle, DNA Repair and Cell Motility-Associated Gene Expression When Compared to G-CSF Mobilization Alone.

AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Months Report from the Phase 3 Study of Plerixafor+G-CSF VS. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with NHL.

12 Months Report from a Phase 3 Study of Plerixafor+G-CSF Vs. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with Multiple Myeloma

Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Following Autologous Hematopoietic Stem Cell Transplant in Patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma.

The CXCR4-Antagonist AMD3100 Augments the Number of Mobilized Peripheral Blood Progenitor Cells (PBPC) When Added to a G-CSF Standard Mobilization Regime and AMD3100-Mobilized PBPC Result in Rapid Hematopoietic Reconstitution after Autologous Transplantation.

The CXCR4 Antagonist AMD3100 Mobilizes a More Primitive Subset of CD34+ Cells Than G-CSF.

CD34+ Cells Mobilized with the New CXCR4 Antagonist AMD3100 + G-CSF Show Increased Anti-Apoptotic, Cell Cycle, DNA Repair and Cell Motility-Associated Gene Expression When Compared to G-CSF Mobilization Alone.

AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only